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If you live on the frontier long enough civilization might 
catch up with you if you are not careful and are not pre- 
pared to move on. I have spent the past two and a half 
decades working at one or more of the interfaces between 
chemistry and biology, first in the Chemistry and Biology 
Departments at Massachusetts Institute of Technology 
(MIT) then for the past 11 years in the Biological Chem- 
istry and Molecular Pharamacology Department, created 
by a fusion of two pre-existing departments, at Harvard 
Medical School. My research group has addressed prob- 
lems in biological catalysis and molecular medicine, using 
whatever input we can assimilate from synthetic and medi- 
cinal chemistry, structural biology, experimental therapeu- 
tics, and molecular microbiology. First, chemical colleagues 
were suspicious that I wasn’t a real chemist, whereas from 
the biology side my scientific dialect was not biological 
enough. Then the chemistry-biology interface became 
more fashionable and activities got renamed, always an 
upscale sign, for example to chemical biology. Now we 
should worry about whether this frontier is closing and we 
should be finding the new ones that are opening. 
On the other hand, “there are no boring problems only 
boring people” a mentor once related scarily to me. There 
are, of course, always challenges and opportunities at the 
interstices of well-defined, even vital, disciplines, provided 
we have the right ways to look at problems. For chemists 
and biologists who regularly use chemical intuitions to 
analyze biological logic, in the contemporary ferment 
enriched by the massive increases in genomic information 
there are three currents that swirl to the surface that will 
percolate through many of the future efforts of chemical 
biologists and biological chemists. 
lnterdisciplinarity and information 
It is a definitional truism that biochemistry/chemical 
biology is an interdisciplinary effort and this is not a 
novel perception as biochemistry departments have 
already existed for many decades. On the other hand, the 
discipline has now circled back and caught fresh cur- 
rency in Chemistry Departments, evinced at least anec- 
dotally by name changes in the Chemistry Departments 
at the University of Colorado, Boulder and at Harvard, 
that reinforce chemical biology as a legitimately central 
focus of chemistry faculty and students. Reciprocally, 
most research-active cell and molecular biologists name 
interdisciplinary approaches as the core of the paradigm 
for future projects and have begun to search for substan- 
tively broader definitions of what talents will be essential 
in research-vigorous departments. Most notably, many 
would now trade for applied mathematicians, computer 
scientists, bioinformation experts, even some types of 
engineers. There is developing consensus that such col- 
leagues are no longer peripheral elements in biologists’ 
futures even if there is no easy plan for how to reshape 
Biology Department boundaries for such a seamless 
intellectual continuum. 
What is clear in this continuum is that chemical 
biology/biological chemistry efforts are going to be an 
information-driven science. The most obvious new intel- 
lectual activity that has firmly and vigorously invaded the 
biology community in the mid/post genomics era is the 
torrent of information from DNA sequencing. By and 
large, biologists and chemists are amateurs, not only in 
gathering and processing information but also in algorithm 
development and evaluation to assess and order such 
information. Like quondam definitions of morality, I and 
most of my colleagues might have trouble defining (rele- 
vant) informatics but we know it when we see it and need 
it. It is painfully obvious that most current investigators 
need broadened training and retraining in informational 
sciences to cope with both the biological and chemical 
attributes of their inquiries. 
Take the combinatorial chemical library phenomenon as 
an example. Given the promise and partial reality of hun- 
dreds of thousands of molecules in synthetic, directed 
libraries along with the rapid advances in automation and 
miniaturization of assays, high-throughput screens look to 
provide high-affinity ligands for almost any biological 
target of interest. At the very least this would advance 
chemogenetics approaches to an equal footing with 
‘knockouts’ to test the function of any biological target in 
any desired milieu. Most biochemists and more biologists 
will find it difficult to evaluate ab initio the quality of 
these molecular libraries, but almost all will want library 
cards from their chemical colleagues. The criteria for 
library design, such as the use of high quality molecules 
with high functional group density and architectural com- 
plexity, reminiscent of therapeutically important natural 
products, will remain frontier efforts for synthetic and 
natural product chemists, at least in the short term. 
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Systems approaches and mesoscale science 
As increases in information about molecules, both small 
molecules as noted above and also biological macromol- 
ecules such as genes, RNAs, and proteins, careen along 
exponentially, there is a parallel fixation of biochemical 
and biological scientists on systems approaches as a central 
manifestation of their interdisciplinary foci. This encom- 
passes, for example, both genome and proteome elucida- 
tions, as well as contemporary approaches to defining 
programs of development or programmed cell death, plas- 
ticity of the nervous system, and pharmacogenetics and 
predictive medical therapies targeted to individual geno- 
types. This systems bias also undergirds such superficially 
disparate efforts as cataloging gene activity temporally and 
spatially through RNA transcriptional profiling or SELEX 
enrichments for tightbinding or catalytic RNAs as well as 
plans to assess the family of all common protein folds both 
by predictive algorithms and high-throughput X-ray crys- 
tallographic consortia. Systems thinking is a pervasive 
modern condition in this set of scientific interfaces despite 
the lack of any formal training of chemists and biologists 
in any of the paradigms of systems dynamics, decision the- 
ories or artificial intelligence. These are skill sets that will 
be central intellectual tools for the next generation of 
chemical biologists/biological chemists. 
Systems approaches and interdisciplinary inputs already 
have two consequences that will probably intensify and 
help move the frontiers. The first is, arguably, that research 
at the chemistry-biology interface is going, or has already 
gone, mesoscale and the second is the integration of the 
engineering ethos into these branches of science. Histori- 
cally, the academic life sciences research model enabled by 
National Institutes of Health (NIH) support and especially 
embraced in the embraced in the individual investigator- 
initiated research paradigm of the National Institute of 
General Medical Sciences (NIGMS) has been to people 
the frontier individually, lab by lab, principal investigator 
by principal investigator. At my university there has been 
an oft-quoted institutional aphorism: “every tub on its own 
bottom”. This competition-based, peer-reviewed, individ- 
ual-centered meritocracy should, and will, persevere but 
lessons from experimental physics and even astronomy 
have ever more currency. The ongoing genome efforts 
and incipient proteome activities are biological inquiries 
practiced in a different way, with dozens of scientists con- 
tributing to, and required for, the overlapping and com- 
plementary skill sets for these informationally expansive 
tasks. This Manhattan project mentality might not be a 
one-time event that will pass from the scene when genome 
victory is declared. It is equally likely that this effort will 
have helped transform many of the norms for self-organi- 
zation of life sciences research. Consortia of scientists 
are most probably required to implement functional 
genomics, to incorporate synthetic chemistry, chip design, 
high-throughput screens and sophisticated analytical and 
informational science to span approaches such as cryoelec- 
tron-microscopic imaging, microfluidics-based analysis of 
cell function, tandem mass spectrdmetry to detect minute 
quantities of thousands of proteins in a microliter of biolog- 
ical fluid and neural network analysis. The biotechnology 
and research-intensive pharmaceutical companies acting to 
functionalize genomics are already organized into, and 
operating within, such mesoscale matrices. 
If a consortium, academic, industrial or mixed, wants to 
study all the attributes of one or more G-protein-coupled 
signal transduction signaling systems, a plethora of exper- 
tise will be required. Initial recognition of ligands at cell 
surfaces to anastomosing pathways that integrate and 
diverge through the many transient protein complexes in 
the cytoplasm to the combinatoric multitudes of transcrip- 
tional readouts from specific gene activation in the 
nucleus suggest a call for mesoscale collections of life sci- 
entists. The technology for planning and executing exper- 
iments may demand such cooperation on several counts, 
including cost, availability and competence. For example, 
affymetrix chips and Fourier transform MS-MS mass 
spectrometers could be so expensive, to say nothing of the 
1 Gigahertz NMR instruments, that they exacerbate a 
‘haves and have nots’ differential accessibility to research 
resources for frontier biomedical science. 
An engineering ethos 
The preceding comments raise the explicit recognition 
that systems focus and interdisciplinarity, among chemi- 
cal biologists in particular and life scientists in general, 
are key defining elements of an engineering ethos. When 
molecules were the primary focus of this scientific micro- 
community it might have been acceptable to define engi- 
neering and engineers as peripheral to core activity in 
chemistry and biology. Now, the pervasive metaphors of 
molecular machines in cells and the notions of reagents, 
from high-affinity ligands to knockout mice, as molecular 
tool kits to take apart and rebuild the processes of the 
cell, from cell-cycle control to chromosome condensation 
and translocation, to molecular motors, to the assembly 
and control of ribosomes, proteasomes and splicesomes, 
illustrate how widespread the nanoscale engineering para- 
digm has become in our thinking. Inter a&z this should 
place at this frontier research-driven engineering institu- 
tions such as MIT, CalTech and Carnegie-Mellon in a 
catalytically central role, not only to redefine the patterns 
of collaborations with Chemistry and Biology Depart- 
ments but also to help educate and train new variants of 
chemical biologists who appreciate mesoscale science 
explicitly. This agenda is separate from and complemen- 
tary to the canonical view that most chemists and biolo- 
gists have of bioengineering efforts. 
Among the challenges that follow are the attendant ques- 
tions of how academic scientists restructure departmental 
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organizations to incorporate nontraditional skill sets into 
both their faculty and students. Fruitful redefinition of 
core knowledge sets almost always starts with graduate 
education and radiates downwards, so new initiatives in 
graduate training, including novel coalitions and defini- 
tions of training grant programs, might be worth careful 
attention. Because chemists and biologists in academic 
centers over the past forty years have had little real 
impetus or experience in working in consortia or 
mesoscale group enterprises the challenges for self-organi- 
zation will be interesting and varied. Enlightened scholar- 
ship and appreciation of the changing patterns at the 
frontiers by the leadership at NIH and by such organiza- 
tions as the Howard Hughes Medical Institute and the 
Wellcome Trust will be crucial in helping to catalyze 
these changes, as they have been in the past. 
